vaatflexibiliteit arterial stiffness
Conditions
Interventions
The egg protein hydrolysate or placebo (amylum as inert filling material) will
be given to the participants in capsules. The subjects will take the
hydrolysate or placebo capsules (5 gr/day) on stud
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - No allergy to chicken egg protein - Age between 18 and 70 years - Male and female - Body Mass Index (BMI) between 25-35 kg/m2 - Diagnosed T2DM (use of antidiabetic drugs and/or a diabetic diet is allowed) or impaired glucose tolerance (IGT) defined as blood glucose > 7.0 mmol/L and
Exclusion criteria
Exclusion criteria: - Active cardiovascular disease like congestive heart failure or recent ( 21 units per week) - Pregnant or breastfeeding women - Current smoker - Having donated blood at the blood bank within a period of 8 weeks prior to the start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint will be the change (baseline versus 2 hours, and baseline versus 2 days) arterial stiffness measured as carotid-femoral pulse wave velocity after consumption of the egg protein hydrolysate. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary study endpoints will be the changes in plasma glucose and insulin concentrations and calculated HOMA-index, incretins, changes in serum lipids, changes in characteristics of the microcirculation as assessed by fundusphotography, changes in non-invasively assessed upper-arm blood pressure and Sphygmocor-derived central aortic systolic blood pressure and heart rate changes after the use of hydrolysate. | — |
Countries
Netherlands
Outcome results
None listed